Masimo Corporation MASI announced preliminary financial results for second-quarter 2024 on Jul 9. Following this release, the company’s shares edged up 0.1% in the after-hours trading session. The company is expected to release second-quarter results on Aug 13, 2024. Prelim Q2 in Detail Per the preliminary release, second-quarter 2024 consolidated revenues are likely to be $496 million, up 9% year over year on a reported basis. The Zacks Consensus Estimate is pegged at $493.5 million. At constant exchange rate (CER), revenues are expected to improve 10.1% year over year. Healthcare revenues are expected to be $344 million, up 22.4% on a reported basis and 23.1% at CER year over year. Non-healthcare revenues are expected to be $152 million, down 12.6% and 10.9% year over year on a reported basis and at CER, respectively. Per management, the incremental value of new healthcare contracts is expected to be $134 million, while driver shipments are expected to be 58 thousand during the second quarter of 2024. Guidance Management plans to provide updated financial guidance for 2024 on the second-quarter earnings call. A Brief Q2 Analysis Per management, Masimo witnessed strength in its healthcare business in the second quarter, along with a strong order backlog as it enters the third quarter. Sensor utilization and hospital census have also improved from 2023. The company also achieved a record second quarter in terms of converting customers to Masimo’s technologies, with an expected $134 million of incremental contract value. These look promising for the stock. On first-quarter 2024 earnings call in May, management stated that the majority of its sensor production is in Malaysia. Management expects this to provide great opportunities for increases in profitability. Increased contributions from Malaysia are likely to have a positive impact on second-quarter revenues. In July, the company announced that the Masimo W1 Sport advanced health tracking wearable is now equipped with a new feature — scientifically based sleep analysis with Sleep Halo. In June, Masimo, along with Cleveland Clinic, announced the launch of a new partnership centered around hospital-based remote patient monitoring, including TeleCritical Care. These raise our optimism about the stock. Price Performance Shares of the company have gained 14.4% between Apr 1 and Jun 29, 2024, compared with the industry’s 8.3% rise and the S&P 500’s 17.2% growth. Zacks Investment Research Image Source: Zacks Investment Research Zacks Rank & Other Key Picks Currently, Masimo carries a Zacks Rank #2 (Buy). A few other top-ranked stocks in the broader medical space are DaVita Inc. DVA, Stryker Corporation SYK and Ecolab Inc. ECL. DaVita, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 13.6%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 29.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. DaVita’s shares have gained 14.4% compared with the industry’s 17.2% rise between Apr 1 and Jun 29, 2024. Stryker, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 10.6%. SYK’s earnings surpassed estimates in each of the trailing four quarters, with the average being 4.9%. Stryker has gained 14.2% compared with the industry’s 2.3% rise between Apr 1 and Jun 29, 2024. Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 14.3%. ECL’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 1.3%. Ecolab’s shares have rallied 21.8% against the industry’s 19.2% decline between Apr 1 and Jun 29, 2024. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ecolab Inc. (ECL):Free Stock Analysis Report Stryker Corporation (SYK):Free Stock Analysis Report DaVita Inc. (DVA):Free Stock Analysis Report Masimo Corporation (MASI):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Masimo (MASI) Preliminary Q2 Results Aided by Healthcare Unit
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...